United Therapeutics Corporation (UTHR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 238.26 |
| Open | 236.28 |
| Bid | 234.19 x 200 |
| Ask | 234.83 x 200 |
| Day's range | 233.31 - 237.71 |
| 52-week range | 204.44 - 261.54 |
| Volume | |
| Avg. volume | 481,744 |
| Market cap | 10.396B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 11.83 |
| EPS (TTM) | 19.80 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 295.18 |
ZacksWhat Makes United Therapeutics (UTHR) a New Buy Stock
United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
ZacksStevanato Group (STVN) to Report Q1 Results: What You Should Expect
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.